Fundraising FoxProlifagen
Doylestown, US · Founded 2025 · Delaware corporation
Find your way into Prolifagen
Sign up to see every warm intro you have to Prolifagen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Prolifagen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Prolifagen develops microRNA (miR) technology to stimulate the regeneration of heart muscle damaged by myocardial infarction, aiming to prevent scar tissue formation and restore cardiac function. The company targets physicians and heart attack patients seeking solutions to prevent heart failure and recurrent cardiac events.
Founders & leadership
AB
Andreas BaderExecutive
MB
Michael BehrChief Executive OfficerMichael Behr is an executive with experience building and commercializing life science startups. He leads Prolifagen, which develops microRNA technology to stimulate heart muscle regeneration following myocardial infarction.
CB
Claudine BruckNamed on SEC filing
Board
MA
M. Alexander ShawBoard director
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2025
▶$3MraisedSep 2025 · 6 investors · BiotechnologyRule 506(b)
▶$3MraisedSep 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- M. Alexander ShawDirector
- Andreas BaderExecutive Officer
- William HoustonExecutive Officer
- Michael BehrExecutive Officer, Director
- Claudine BruckExecutive Officer, Director
- Amount sold
- $3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
ExagenExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
NivagenNivagen provides drug product development services, guiding pharmaceutical companies through the full lifecycle from concept to commercialization, including traditional NDAs, 505(b)(2)s, and complex generics. The company serves pharmaceutical and biotech firms seeking to bring innovative drug products to market with intellectual property protection and accelerated timelines.
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Companies working in the same space as Prolifagen.
In the news
Frequently asked questions
- What does Prolifagen do?
- Prolifagen develops microRNA (miR) technology to stimulate the regeneration of heart muscle damaged by myocardial infarction, aiming to prevent scar tissue formation and restore cardiac function. The company targets physicians and heart attack patients seeking solutions to prevent heart failure and recurrent cardiac events.
- How much funding has Prolifagen raised?
- Prolifagen has disclosed $3M raised across 1 round.
- Where is Prolifagen headquartered?
- Prolifagen is headquartered in Doylestown, US.